Supplementary Data

Supplementary Table 1. Digital MIQE2020 guidelines (dMIQE2020) checklist.

ITEM TO CHECK	PROVIDED	COMMENT
	Y/N	
1. SPECIMEN		
Detailed description of specimen type and numbers	Y	Materials and Methods, references
Sampling procedure (including time to storage)	Y	Materials and Methods, references
Sample aliquotation, storage conditions and duration	Y	Materials and Methods, references
2. NUCLEIC ACID EXTRACTION		
Description of extraction method including amount of sample processed	Y	Materials and Methods, references
Volume of solvent used to elute/resuspend extract	Y	Materials and Methods, references
Number of extraction replicates	Y	Materials and Methods, references
Extraction blanks included?	N	
3. NUCLEIC ACID ASSESSMENT AND STORAGE		
Method to evaluate quality of nucleic acids	Y	Materials and Methods
Method to evaluate quantity of nucleic acid	Y	Materials and Methods
Storage conditions: temperature, concentration, duration, buffer, aliquots	N	
Clear description of dilution steps used to prepare working DNA solution	N	
4. NUCLEIC ACID MODIFICATION		

Template modification (digestion, sonication, pre-amplification, bisulfite etc.)	Y	Bisulfite conversion: Materials and Methods, references
Re-extraction performed?	Y	Materials and Methods, references
5. REVERSE TRANSCRIPTION	N	
cDNA priming method + concentration		Not Applicable
One or two step protocol (include reaction details for two step)		Not Applicable
Amount of RNA used per reaction		Not Applicable
Detailed reaction components and conditions		Not Applicable
Estimated copies measured with and without addition of RT		Not Applicable
Manufacturer of reagents used and catalogue number		Not Applicable
Storage of cDNA: temperature, concentration, duration, buffer, aliquots		Not Applicable
6. dPCR OLIGONUCLEOTIDES AND TARGET INFORMATION		
Sequence accession number	N	Commercial kit: Bio-Rad ddPCR MSI RUO Kit
Location of amplicon	N	Commercial kit: Bio-Rad ddPCR MSI RUO Kit
Amplicon length	N	Commercial kit: Bio-Rad ddPCR MSI RUO Kit
Primer and probe sequences (or amplicon context sequence)	N	BAT-25
		TAAATTAGAACAGGAATTCCAAAGAGACAGCAGTT GGAACATGAAGAAACTAAATTTCCTCTGCTTTTGGT TACCACACTTCAAAATGACATTCTGCATTTTAACTA TGGCTCTAAAATGCTCTGTTCTCAAAAAAAAAA
		BAT-26

		TTAGAACTCTTATCAGATGATTCCAACTTTGGACAG TTTGAACTGACTACTTTTGACTTCAGCCAGTATATG AAATTGGATATTGCAGCAGTCAGAGCCCTTAACCT TTTTCAGGTAAAAAAAAAA
		NR-21 TGCTACTCTCTAAAAAAGGCAAGCAGATAAAAGAGAACACGAAAAATATTCCTACTCCGCATTCACACTTTCTGGTCACTCGCGTTTACAAACAA
		NR-24 GGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGG CGGACGTTGCAGTGAGCGGAGATTGTGCATTCCAACCTGGGTGACAGAGTGAGACTCTGTCTCA CAAAAAAAAAA
		Mono-27: GGCAGGAAATGGTGGGAACCCAGGGGGTGGAGA TTGCAGTGAGCTGAGATTGCGCCACTGCACTCCAG CGTGGGAGACAGAGCAAGACTCTGCCTCAAAAAA AAAAAAAAAA
Location and identity of any modifications	N	Commercial kit: Bio-Rad ddPCR MSI RUO Kit
Manufacturer of oligonucleotides	N	Commercial kit: Bio-Rad ddPCR MSI RUO Kit
7. dPCR PROTOCOL		
Manufacturer of dPCR instrument and instrument model	Y	Bio-Rad Laboratories QXDx ddPCR System

Buffer/kit Catalogue No and manufacturer	Y	Commercial kit: Bio-Rad ddPCR MSI RUO Kit
Primer and probe concentration	N	
Pre-reaction volume and composition (incl. proportion of template added)	Y	6.6ul sample per 22ul reaction
Template treatment (initial heating or chemical denaturation)	N	
Polymerase identity and concentration, Mg++ and dNTP concentrations	N	
Complete thermocycling parameters	Y	Materials and Methods
8. ASSAY VALIDATION		
Details of optimisation performed		Bio-Rad ddPCR MSI RUO Kit User Guide
Analytical specificity (vs. related sequences)		Bio-Rad ddPCR MSI RUO Kit User Guide
Analytical sensitivity (LoD)	Y	Bio-Rad ddPCR MSI RUO Kit User Guide
Testing for inhibitors (from biological matrix/extraction)	N	Not performed
9. DATA ANALYSIS		
Description of dPCR experimental design	Y	Materials and Methods
Comprehensive details +ve and -ve of controls (whether applied for QC or for estimation of error)	Y	Materials and Methods: positive and negative controls included as part of kit on every plate.
Examples of +ve and -ve experimental results (in supplemental materials)	Y	In results
Description of technical replication	Y	Materials and Methods
Repeatability (intra-experiment variation)	Y	Materials and Methods
Reproducibility (inter-experiment/user/lab etc. variation)	N	

Number of partitions measured (average and standard deviation)	Y	Materials and Methods
Partition volume used	N	
Copies per partition (λ or equivalent) (average and standard deviation)	N	
dPCR analysis program (source, version)	Y	QuantaSoft Analysis Pro v1.0 (manual threshold) QX Manager Premium Edition v2.0.0.456 (auto-threshold)
Description of normalisation method	N	Material and Methods: dPCR manual thresholding and auto- thresholding was normalized to the mean cluster densities of the positive controls run on every plate.
Statistical methods used for analysis	N	A Poisson distribution analysis was performed on the dPCR data to calculate copies per ul.
Data submission using RDML	N	Availability of data upon request following all necessary regulatory requirements.

Supplementary Table 2. Validation results obtained for the analysis of FFPE samples using the auto-thresholding algorithm. Of the over 200 contrived and CRC patient FF, FFPE and cfDNA samples used to develop the auto-thresholding algorithm 60 were FFPE (47 MSI-H and 13 MSS) and 22 were cfDNA (14 MSI-H and 8 MSS), and were used to train the neural network. Another 94 FFPE, 24 MSI-H and 70 MSS, were used to validate the auto-thresholding algorithm. The validation results are shown in the table.

Sample Type	n	Vendor MSI Status*	MSI Samples by ddPCR MSI		Overall Concordance		
FFPE	24	MSI-H	23	95.8%	06.40/		
FFFE	70**	MSS	67	95.7%	96.4%		

^{*}Orthogonal data is immunohistochemistry of mismatch repair proteins

^{**20} are FFPE of colon tissue from normal patients and presumed MSS

Supplementary Table 3. Summary of all ddPCR Microsatellite Instability (MSI) RUO kit data that was excluded from the analysis due to a failure or low droplet count of <10,000.

Sample	Sample Type	ddPCR MSI Assay	Reason for Exclusion						
Alg-10	FF/FFPE	1	Low droplet count of 4698						
Alg-11	FF/FFPE	2	Low droplet count of 8603						
Alg-14	FF/FFPE	3	Low droplet count of 2006						
Alg-14	FF/FFPE	2	Unsuccessful droplet generation, no droplets detected						
Alg-16	FF/FFPE	1	Low droplet count of 1396						
Alg-16	FF/FFPE	2	Unsuccessful droplet generation						
Alg-23	FF/FFPE	1	Low droplet count of 3699						
Alg-28 FF/FFPE		2	Unsuccessful droplet generation, no droplets detected						
Alg-34	FF/FFPE	3	Low droplet count of 3342						
Alg-51	FF/FFPE	2	Unsuccessful droplet generation						
Alg-58	FF/FFPE	2	Low droplet count of 3047						
Alg-58	FF/FFPE	3	Low droplet count of 5056						
Alg-61	FF/FFPE	3	Low droplet count of 2816						
Alg-67	FF/FFPE	2	Low droplet count of 5493						
Alg-70	FF/FFPE	3	Low droplet count of 5938						
Alg-73	FF/FFPE	1	Insufficient plate seal before thermal cycling						
Alg-91	FF/FFPE	3	Low droplet count of 7958						
Alg-93	FF/FFPE	1	Low droplet count of 675						
Ras-95	cfDNA	3	Cluster mirroring						

Supplementary Table 4. Concordance of FF and FFPE tissues from colorectal cancer patients between auto-thresholded ddPCR MSI with the Promega MSI Analysis System v1.2 (A). There were twelve samples that were not concordant for all markers: Samples †Alg-96; *Alg-25, Alg-67; *Alg-99, Alg-45, Alg-30, Alg-43, Alg-53, Alg-63; **Alg-17; ††Alg-88; §Alg-28. For Alg-28, the same 4 markers were not unstable for both ddPCR MSI and the MSI Analysis System v1.2. Eleven samples were re-tested with the MSI Analysis System v1.2 (Alg-67 not re-tested) (B). Seven of these were concordant compared to ddPCR MSI, while four remained discordant by marker: Sample *Alg-25 & Alg-67, *Alg-99, *Alg-30, *Alg-28.

Promega MSI Analysis (tissue DNA), Historical A **MSS** MSI-H 2 0 1 3 4 5 0 83 MSS 1† ddPCR MSI 2* 2 **Auto-threshold** 3 1‡ (tissue DNA) MSI-H 18 4 1^{I} 5 **4**¶ 1* 1 7

> Promega MSI Analysis + Discordant Repeat Result (tissue DNA), Historical

MSS MSI-H 2 0 1 3 5 83 **MSS** 1 1 ddPCR MSI 2* 1^{\dagger} 2 **Auto-threshold** 3 (tissue DNA) MSI-H 18 4 1¶ 5 13

B

Supplementary Table 5. Concordance of FF and FFPE tissues from colorectal cancer patients between manual thresholded ddPCR MSI with the Promega MSI Analysis System v1.2 (**A**). There were fourteen samples that were not concordant for all markers: Sample [†]Alg-1, Alg-67, Alg-96, Alg-99; *Alg-25; ¹Alg-45; ¹Alg-30, Alg-43; **Alg-53, Alg-63; [‡]Alg-17; ⁸Alg-28; ^{††}Alg-88; [‡]Alg-75. For Sample Alg-28, the same 4 markers were not unstable for both ddPCR MSI and the MSI Analysis System v1.2. Twelve of the fourteen samples were retested with the MSI Analysis System v1.2 (**B**). Sample Alg-1 and Alg-67 not retested. Seven of these were concordant compared to ddPCR MSI, while five remained discordant by marker: Sample [†]Alg-1, Alg-67; *Alg-25; [¶]Alg-30, [‡]Alg-75; [§]Alg-28, Alg-43. The concordance by MSI status was high at 101 of 102 (**C**).

A	Promega MSI Analysis (tissue DNA), Historical									
	M	SS	MSI-H							
			0	1	2	3	4	5		
	MSS	0	82							
	MSS	1	4^{\dagger}							
ddPCR MSI Manual		2	1*							
Threshold (tissue DNA)	MSI-H	3						1#		
(dssuc DNA)	MSI-II	4		2¶			1§			
		5	11	2*	1*		1†	6		

Promega MSI Analysis + Discordant Repeat Result (tissue DNA), Historical

), His		
			M	I-H				
			0	1	2	3	4	5
	MSS	0	82					
	MSS	1	2 [†]	2				
ddPCR MSI Manual		2	1*					
Threshold (tissue DNA)	MOLII	3						1‡
(ussue DNA)	MSI-H	4				1¶		2§
		5						11

B

 \mathbf{C}

Promega MSI Analysis system + Discordant Repeat Test

ddPCR MSI	
Manual Threshol	d

	MSS	MSI-H
MSS	86	0
MSI-H	1	15

Supplementary Table 6. Comparison of ddPCR MSI with auto-thresholding for 14 FF and FFPE samples when tested at an input per well of 18, 5 and 1 ng/well, measured by Qubit dsDNA BR Assay. Seven (7) of the samples were determined as MSS and 7 as MSI-H by the Promega MSI Analysis System. The ddPCR MSI results reflect data for replicate 2 of a total of 2 replicates.

		Pr	ome	ega I	MSI	Analysis	ddl	ddPCR MSI - 18 ng/rxn					ddPCR MSI - 5 ng/rxn					ddPCR MSI - 1 ng/rxn						
Sampl e	RAT.25	BAT-26	NR.21	NR-24	Mono-27	Status	BAT-25	BAT-26	NR-21	NR-24	Mono-27	Statu s	BAT-25	BAT.26	NR.21	NR-24	Mono-27	Stat us	RAT.25	R∆T.26	NR.21	NR-24	Mono.27	Statu s
Alg-1			,	1	1	MSS	1	1	-	-	-	MSS	-			+	,	MSS			1		,	MSS
Alg-2	-				1	MSS	1	1	-	-	-	MSS	-	-	-	-		MSS	-		1		+	MSS
Alg-14	-				,	MSS	-	,	n a	na	na	na	_	-	-	_		MSS	-				,	MSS
Alg-16	-	-			-	MSS	n a	n a	n a	na	-	na	-	-	-	-		MSS	-			-		MSS
Alg-67	-	-		- 1	- 1	MSS	-	+	n a	na	-	na	-	+	-	-		MSS	-		-	-	+	MSS
Alg-87		1				MSS	1	1	-	-	-	MSS			1	-		MSS				1		MSS
Alg- 100	-	-	-	-	-	MSS	_	-	-	-	-	MSS	_	-	-	_	-	MSS	-	-	-	-	-	MSS
Alg-28	+	+	+	+	+	MSI-H	+	+	+	+	- 1	MSI-H	+	+	+	+	-	MSI- H	+	+	+	+	+	MSI-H
Alg-30	+	+	+	1		MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI-H
Alg-33	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI-H
Alg-43	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI-H
Alg-58	+	+	+	+	+	MSI-H	+	+	n a	na	na	na	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI-H
Alg-83	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI-H
Alg-89	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI-H



Supplementary Table 7. Comparison of ddPCR MSI with manual thresholding for 14 FF and FFPE samples when tested at an input per well of 18, 5 and 1 ng/well, measured by Qubit dsDNA BR Assay. Seven (7) of the samples were determined as MSS and 7 as MSI-H by the Promega MSI Analysis System. The ddPCR MSI results reflect data for replicate 1 of a total of 2 replicates.

	Promega MSI Analysis					ddl	PCR I	MSI -	18 ng/	rxn	ddPCI	R MS	SI - S	5 ng	/rxn	kn ddPCR MSI - 1 ng/rxn								
Sampl e	BAT.25	BAT.26	NR-21	NR-24	Mono-27	Status	BAT-25	BAT-26	NR-21	NR-24	Mono-27	Statu s	RAT.25	B∆T.26	NR-21	NR-24	Mono-27	Stat us	BAT-25	BAT-26	NB-21	NR-24	Mono.27	Statu s
Alg-1	-	-		-		MSS	1	+	-	-	,	MSS		ı			,	MSS	-	-	-	,		MSS
Alg-2	_	-	_	-	-	MSS	-	-	-	-	-	MSS	-	-	-	-	-	MSS	_	_	-	-	_	MSS
Alg-14	_	-	_	-	-	MSS	-	-	-	-	-	MSS	-	-	-	-	-	MSS	_	_	-	-	_	MSS
Alg-16	-	-		-	-	MSS	-	1	-	-	-	MSS	-	- 1	1	-	-	MSS	-	_	-	-	-	MSS
Alg-67	-	-		-	-	MSS	-	+	-	-	-	MSI-H	-	+	-	-	-	MSS	-	-	-	-		MSS
Alg-87	-	-	-	-	-	MSS	-	1	-	-	,	MSS	-	1	1	-	-	MSS	_	_		-	-	MSS
Alg- 100	-	-		-		MSS	-	1	-	-	,	MSS	-					MSS	-	-	-			MSS
Alg-28	+	+	+	+	+	MSI-H	+	+	+	+	-	MSI-H	+	+	+	+	-	MSI- H	-	+	+	+	-	MSI- H
Alg-30	+	+	+	_	_	MSI-H	+	+	+	_	+	MSI-H	+	+	_	-	+	MSI- H	+	+	+	+	_	H SI-
Alg-33	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI- H
Alg-43	+	+	+	+	+	MSI-H	+	+	+	+	-	MSI-H	+	+	+	+	-	MSI- H	+	+	+	+	-	MSI- H
Alg-58	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI- H
Alg-83	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI- H
Alg-89	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI- H

-	stable
+	unstable
na	failed

Supplementary Table 8. Comparison of ddPCR MSI with manual thresholding for 14 FF and FFPE samples when tested at an input per well of 18, 5 and 1 ng/well, measured by Qubit dsDNA BR Assay. Seven (7) of the samples were determined as MSS and 7 as MSI-H by the Promega MSI Analysis System. The ddPCR MSI results reflect data for replicate 2 of a total of 2 replicates.

	Promega MSI Analysis					ddl	PCR I	MSI -	18 ng/	rxn	ddPC	R M	SI -	5 ng	/rxn		ddPCR MSI - 1 ng/rxn							
Sampl e	BAT-25	RAT.26	NR-21	NR-24	Mono-27	Status	BAT-25	BAT-26	NR-21	NR-24	Mono-27	Statu s	RAT.25	R∆T.26	NR-21	NR-24	Mono-27	Stat us	RAT.25	R∆T.26	NR.21	NR-24	Mono.27	Statu s
Alg-1		-		-	1	MSS	1	+	-		-	MSS	-	ı		,		MSS			1		-	MSS
Alg-2	-	-		-	1	MSS	1	1	-	-	-	MSS	-				,	MSS	-		1	-	,	MSS
Alg-14	_	-				MSS	-		n a	na	na	na	-					MSS	_			-		MSS
Alg-16	-	-	-	-	-	MSS	n a	n a	n a	na	-	na	-	-	-	-	-	MSS	-	-	-	-	-	MSS
Alg-67	-	-	-	-	-	MSS	-	+	n a	na	-	na	-	+	-	-	-	MSS	-	-	-	-	-	MSS
Alg-87		-		-	1	MSS	1	1	-		-	MSS	-	ı		,		MSS			1		-	MSS
Alg- 100		-		-		MSS	,	,	-	-	-	MSS	-					MSS	-			-		MSS
Alg-28	+	+	+	+	+	MSI-H	+	+	+	+		MSI-H	+	+	+	+	- 1	MSI- H	+	+	+	+		MSI- H
Alg-30	+	+	+			MSI-H	+	+	+		+	MSI-H	+	+		+	+	MSI- H	+	+		-	+	MSI- H
Alg-33	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI- H
Alg-43	+	+	+	+	+	MSI-H	+	+	+	+		MSI-H	+	+	+	+		MSI- H	+	+	+	+	,	MSI- H
Alg-58	+	+	+	+	+	MSI-H	+	+	n a	na	na	na	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI- H
Alg-83	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI- H
Alg-89	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI-H	+	+	+	+	+	MSI- H	+	+	+	+	+	MSI- H



Supplementary Table 9. Intra- and inter-run reproducibility of sample testing. Nine runs for cohort 1 (ALGECOLS) were analyzed for intra-and inter-run reproducibility by analyzing the positive controls run in duplicate for each run. Intra-run analysis of the positive control resulted in a mean difference in mutant fractional abundance ranging from 5.8% to 13.2% across the 5 target loci. The mean difference in wild type concentration for the 3 assays ranged from 2.8% to 3.5%. Inter-run analysis of the positive control resulted in a mutant fractional abundance CV ranging from 4.0% to 9.6% (n = 18) across the 5 target loci. The CV of the wild type concentration ranged from 2.0% to 2.5% (n = 18).

Marker	Mean Difference in Mutant Fractional Abundance	Mean Mutant Fractional Abundance	CV of Mutant Fractional
	between Duplicates	(n = 18)	Abundance (n = 18)
BAT-25	8.1%	7.1%	5.8%
BAT-26	11.4%	6.9%	7.8%
NR-21	13.2%	6.9%	9.6%
NR-24	5.8%	7.5%	4.0%
Mono-27	10.6%	6.0%	7.9%
Wild Type	Mean Difference in Wild	Mean Wild Type	CV of Wild Type
	Type Concentration	Concentration	Concentration (n =
	between Duplicates	$(copies/\mu L) (n = 18)$	18)
Assay 1	3.4%	170.0	2.4%
Assay 2	3.5%	169.5	2.5%
Assay 3	2.8%	172.0	2.0%

Supplementary Table 10. Comparison of duplicate analysis. For cohort 1, 102 samples were run in duplicate within the same run. Eighty-eight (88) of the 102 had valid results for both replicates. Among these 88 samples, the mean difference in wild type concentration for the 3 assays ranged from 4.3% to 4.5%. The marker results for these 88 samples had a 100% match between replicates for 86 of the samples. For the remaining 2 samples, detection of one marker changed from positive to negative because the mutant fractional abundance of these markers was near the limit of detection. These discordant marker results did not change the MSI status determination for these samples. Of the 88 samples, the ddPCR MSI assay determined 16 were MSI-H. The mean difference in mutant fractional abundance for these 16 samples ranged between 2.1% and 6.5% for the 5 target loci.

		ference betw entration of		Standard Deviation of Difference between Wild Type Concentration of Duplicates							
Wild Type	MSS	MSI-H	All	MSS	MSI-H	All					
	>		Samples			Samples					
	$(\mathbf{n} = 72)$	(n = 16)	(00)	$(\mathbf{n}=72)$	$(\mathbf{n} = 16)$	(00)					
			(n = 88)			(n = 88)					
Assay 1	4.2%	4.7%	4.3%	5.3%	6.2%	5.4%					
Assay 2	4.5%	4.4%	4.5%	6.0%	5.6%	5.9%					
Assay 3	4.4%	3.8%	4.3%	5.7%	4.9%	5.5%					
Marker	Mean D	oifference in 1	Mutant	Standard Deviation of Difference in							
	Fractional	Abundance	of MSI-H	Mutant Fractional Abundance of MSI-H							
		n = 16		n = 16							
BAT-25		5.5%		10.0%							
BAT-26		4.1%		7.3%							
NR-21		2.1%		3.1%							
NR-24		6.5%		12.8%							
Mono-27		5.8%		11.5%							